<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771901</url>
  </required_header>
  <id_info>
    <org_study_id>07-1114</org_study_id>
    <nct_id>NCT00771901</nct_id>
  </id_info>
  <brief_title>Effect of Endoplasmic Reticulum Stress on Metabolic Function</brief_title>
  <acronym>TUDCA/PBA</acronym>
  <official_title>Effect of Endoplasmic Reticulum Stress on Metabolic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Normally, the hormone insulin works to help keep blood sugar normal. However, as a person
      gains weight, insulin does not work as well and blood sugar tends to be a little higher than
      normal. This is called &quot;insulin resistance&quot;.

      Two investigational drugs (not approved by the Food and Drug Administration) for the
      treatment of high lipid levels or insulin resistance are being examined in this study: one
      drug is called tauroursodeoxycholic acid (TUDCA), the other is called sodium phenylbutyrate
      (PBA). This study is designed to test if TUDCA and/or PBA is effective in people who are
      obese with insulin resistance and high lipids. We hypothesize that pharmacologically-induced
      decreases in ER stress will improve insulin action and hepatic lipid metabolism in obese
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 4-week randomized, controlled trial will be conducted to evaluate the following specific
      aims in obese subjects:

      Determine the effect of treatment with TUDCA or PBA on:

        1. Body fat distribution: a) intrahepatic triglyceride (IHTG) content, b) intramyocellular
           triglyceride (IMTG) content, and c) intra-abdominal fat content, assessed by using
           magnetic resonance spectroscopy and magnetic resonance imaging.

        2. In vivo insulin sensitivity in adipose tissue (suppression of lipolysis), liver
           (suppression of glucose production), and skeletal muscle (stimulation of glucose
           uptake), assessed by using the hyperinsulinemic-euglycemic clamp procedure in
           conjunction with stable isotope tracer infusion.

        3. VLDL-triglyceride (TG) and VLDL-apolipoprotein-B100 (apoB-100) secretion rates, assessed
           by stable isotopically labeled tracer infusion methods.

        4. Skeletal muscle intracellular insulin signaling, fatty acid oxidation, and markers of
           inflammation, assessed by evaluating skeletal muscle biopsies ex vivo.

        5. Adipose tissue insulin signaling, ER stress, and inflammation, assessed by evaluating
           adipose tissue biopsies ex vivo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Composition</measure>
    <time_frame>Baseline and four weeks</time_frame>
    <description>Fat mass (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity in the Liver</measure>
    <time_frame>Baseline and four weeks</time_frame>
    <description>HISI (hepatic insulin sensitivity index). HISI is the inverse of the product of endogenous glucose production and plasma insulin concentration and provides an index of how well circulating insulin controls the amount of glucose supplied by the liver. A higher number is indicative of greater insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-triglyceride (TG) Concentration</measure>
    <time_frame>Baseline and four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be given a placebo rather than tauroursodeoxycholic acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tauroursodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive tauroursodeoxycholic acid for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive sodium phenylbutyrate for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tauroursodeoxycholic acid</intervention_name>
    <description>1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.</description>
    <arm_group_label>tauroursodeoxycholic acid</arm_group_label>
    <other_name>TUDCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>7 pills daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium phenylbutyrate</intervention_name>
    <description>20g/day for four weeks.</description>
    <arm_group_label>PBA</arm_group_label>
    <other_name>PBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI range 30 to 45

          -  sedentary (defined as regular exercise &lt; 1 h per week or &lt; 2 x/week for the last 6
             months)

        Exclusion Criteria:

          -  active or previous infection with hepatitis B or C

          -  liver diseases

          -  history of alcohol abuse

          -  current alcohol consumption &gt; 20 g/day

          -  severe hypertriglyceridemia ( &gt; 400 mg/dL)

          -  active peptic ulcer disease

          -  taking cholestyramine or oral contraceptives

          -  women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein S. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010 Aug;59(8):1899-905. doi: 10.2337/db10-0308. Epub 2010 Jun 3.</citation>
    <PMID>20522594</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <results_first_submitted>September 15, 2017</results_first_submitted>
  <results_first_submitted_qc>April 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2018</results_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>type II diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-phenylbutyric acid</mesh_term>
    <mesh_term>Tauroursodeoxycholic acid</mesh_term>
    <mesh_term>Taurochenodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants will be recruited by reviewing the VFH database pf research subjects and by local postings. Potential subjects will be contacted by telephone for an initial pre-screen, at which time the study is discussed and a brief medical history and concomitant medication list is obtained. ICF will be sent to interested subjects.</recruitment_details>
      <pre_assignment_details>Screening tests to determine eligibility included: medical hx &amp; PE, blood tests, resting ECG, OGTT, MRI/MRS/MRE of abdomen/liver, and DEXA scan. Two baseline metabolism studies prior to study drug intervention. There were 67 screen fails, 4 subjects withdrew consent before beginning study intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subjects will be given a placebo rather than tauroursodeoxycholic acid.
placebo: 7 pills daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Tauroursodeoxycholic Acid</title>
          <description>Subjects will receive tauroursodeoxycholic acid for four weeks.
tauroursodeoxycholic acid: 1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.</description>
        </group>
        <group group_id="P3">
          <title>Sodium Phenylbutyrate</title>
          <description>Subjects will receive sodium phenylbutyrate for four weeks.
sodium phenylbutyrate: 20g/day for four weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dissat w/# of study medication (40/day)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subjects will be given a placebo rather than tauroursodeoxycholic acid.
placebo: 7 pills daily for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Tauroursodeoxycholic Acid</title>
          <description>Subjects will receive tauroursodeoxycholic acid for four weeks.
tauroursodeoxycholic acid: 1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.</description>
        </group>
        <group group_id="B3">
          <title>Sodium Phenylbutyrate</title>
          <description>Subjects will receive sodium phenylbutyrate for four weeks.
sodium phenylbutyrate: 20g/day for four weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="14"/>
                    <measurement group_id="B2" value="47" spread="9"/>
                    <measurement group_id="B3" value="49" spread="8"/>
                    <measurement group_id="B4" value="47" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Composition</title>
        <description>Fat mass (%)</description>
        <time_frame>Baseline and four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects will be given a placebo rather than tauroursodeoxycholic acid.
placebo: 7 pills daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tauroursodeoxycholic Acid</title>
            <description>Subjects will receive tauroursodeoxycholic acid for four weeks.
tauroursodeoxycholic acid: 1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Phenylbutyrate</title>
            <description>Subjects will receive sodium phenylbutyrate for four weeks.
sodium phenylbutyrate: 20g/day for four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition</title>
          <description>Fat mass (%)</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="7"/>
                    <measurement group_id="O2" value="39" spread="8"/>
                    <measurement group_id="O3" value="37" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="7"/>
                    <measurement group_id="O2" value="39" spread="8"/>
                    <measurement group_id="O3" value="39" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity in the Liver</title>
        <description>HISI (hepatic insulin sensitivity index). HISI is the inverse of the product of endogenous glucose production and plasma insulin concentration and provides an index of how well circulating insulin controls the amount of glucose supplied by the liver. A higher number is indicative of greater insulin sensitivity.</description>
        <time_frame>Baseline and four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects will be given a placebo rather than tauroursodeoxycholic acid.
placebo: 7 pills daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tauroursodeoxycholic Acid</title>
            <description>Subjects will receive tauroursodeoxycholic acid for four weeks.
tauroursodeoxycholic acid: 1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Phenylbutyrate</title>
            <description>Subjects will receive sodium phenylbutyrate for four weeks.
sodium phenylbutyrate: 20g/day for four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity in the Liver</title>
          <description>HISI (hepatic insulin sensitivity index). HISI is the inverse of the product of endogenous glucose production and plasma insulin concentration and provides an index of how well circulating insulin controls the amount of glucose supplied by the liver. A higher number is indicative of greater insulin sensitivity.</description>
          <units>100/ (µmol/min * uIU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.007"/>
                    <measurement group_id="O2" value="0.009" spread="0.004"/>
                    <measurement group_id="O3" value="0.008" spread="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.004"/>
                    <measurement group_id="O2" value="0.012" spread="0.006"/>
                    <measurement group_id="O3" value="0.009" spread="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VLDL-triglyceride (TG) Concentration</title>
        <time_frame>Baseline and four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects will be given a placebo rather than tauroursodeoxycholic acid.
placebo: 7 pills daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tauroursodeoxycholic Acid</title>
            <description>Subjects will receive tauroursodeoxycholic acid for four weeks.
tauroursodeoxycholic acid: 1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Phenylbutyrate</title>
            <description>Subjects will receive sodium phenylbutyrate for four weeks.
sodium phenylbutyrate: 20g/day for four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>VLDL-triglyceride (TG) Concentration</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.33"/>
                    <measurement group_id="O2" value="0.74" spread="0.50"/>
                    <measurement group_id="O3" value="0.89" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.33"/>
                    <measurement group_id="O2" value="0.75" spread="0.56"/>
                    <measurement group_id="O3" value="0.97" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from the time participants signed the informed consent until 30 days after study completion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subjects will be given a placebo rather than tauroursodeoxycholic acid.
placebo: 7 pills daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Tauroursodeoxycholic Acid</title>
          <description>Subjects will receive tauroursodeoxycholic acid for four weeks.
tauroursodeoxycholic acid: 1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.</description>
        </group>
        <group group_id="E3">
          <title>Sodium Phenylbutyrate</title>
          <description>Subjects will receive sodium phenylbutyrate for four weeks.
sodium phenylbutyrate: 20g/day for four weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samuel Klein, M.D.</name_or_title>
      <organization>Washington University School of Medicine in Saint Louis, Missouri</organization>
      <phone>314-362-8708</phone>
      <email>sklein@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

